Search company, investor...

Metastatix

metastatix.com

Founded Year

2005

Stage

Series B | Alive

Total Raised

$39.1M

Last Raised

$35M | 15 yrs ago

About Metastatix

Metastatix is a pharmaceutical company based in Atlanta, GA. Founded in 2005, the company is developing and commercializing small- molecule drugs to treat severely debilitating or life-threatening diseases including cancer, HIV infection, and macular degeneration. Per the company, Metastatix has pioneered the development of a series of oral small-molecule CXCR4 inhibitors that have unprecedented biological activity in preclinical models. The company has licensed its technology from Emory University.

Headquarters Location

1860 Montreal Road

Atlanta, Georgia, 30084,

United States

678-367-0720

Missing: Metastatix's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Metastatix's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing Metastatix

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Metastatix is included in 2 Expert Collections, including Cancer.

C

Cancer

1,179 items

Pharmaceutical and biotechnology companies with cancer therapy drug candidates.

B

Biopharma Tech

15,535 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

Metastatix Frequently Asked Questions (FAQ)

  • When was Metastatix founded?

    Metastatix was founded in 2005.

  • Where is Metastatix's headquarters?

    Metastatix's headquarters is located at 1860 Montreal Road, Atlanta.

  • What is Metastatix's latest funding round?

    Metastatix's latest funding round is Series B.

  • How much did Metastatix raise?

    Metastatix raised a total of $39.1M.

  • Who are the investors of Metastatix?

    Investors of Metastatix include MedImmune Ventures, Centrosome, Georgia Venture Partners, Aurora Funds, CM Capital and 9 more.

  • Who are Metastatix's competitors?

    Competitors of Metastatix include Viamet Pharmaceuticals, OyaGen, Alfama, CoMentis, iPierian and 13 more.

Compare Metastatix to Competitors

CoImmune Logo
CoImmune

CoImmune, fka Argos Therapeutics, is a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases. Using biological components from each patient, the company's immunotherapies employ the patient's dendritic cells to activate an immune response specific to the patient's disease.

C
Calyx Therapeutics

Calyx Therapeutics is a pharmaceutical company focusing on oral therapies for diabetes and inflammatory diseases. Calyx utilizes natural plant extracts with demonstrated clinical activity in humans as the source of its discovery efforts. The company isolates the biologically active molecule, determines its chemical structure, and aims to develop small molecule analogs. This process aims to reduce the time and investment required to take lead molecules into preclinical and clinical testing.

E
Esperance Pharmaceuticals

Esperance Pharmaceuticals develops targeted anticancer drugs that selectively kill cancer cells without harming normal cells.

L
LaGray

LaGray is engaged in the research and development of drugs for the treatment of endemic diseases in Sub-Saharan Africa.

H
Humanetics

Humanetics is a clinical-stage pharmaceutical company engaged in developing and commercializing products to enhance human health and wellbeing in markets with urgent and unmet needs. It has a focus on radiation modulators for oncology, medical imaging, and medical countermeasure uses. The company develops BIO 300, a highly selective modulator of inflammation, cell cycle arrest, and DNA damage repair. Humanetics was founded in 1988 and is based in Minneapolis, Minnesota.

N
Novation Pharmaceuticals

Novation is focusing on the development of small molecular weight drugs that affect the stability of messenger RNA. Initial development efforts are on the treatment and prevention of cancer and chronic inflammatory diseases.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.